health initiative Alys Pharmaceuticals, $100 million received investment. 100 million dollar investment, to heal It was carried out by. The Switzerland-based company announced that it will use the new investment in R&D activities.
John Harris, Brian Kim, Lars French, Craig Mello, Eric Deutsch ve Mark Prausnitz Founded by Alys Pharmaceuticals, it operates in the field of immuno-dermatology. This discipline studies the role of the immune system in skin diseases. The Switzerland-based company collaborates with institutions such as Gustave Roussy, UMass Chan Medical School, Icahn School of Medicine at Mount Sinai, Georgia Institute of Technology and Empa, Swiss Federal Laboratories for Materials Science & Technology.
Alys Pharmaceuticals develops innovative drugs and treatment methods for the treatment of skin diseases. These diseases include skin diseases such as atopic dermatitis, vitiligo, alopecia areata, chronic spontaneous urticaria, and rarer dermatological diseases such as mastocytosis and cutaneous T-cell lymphoma.
The company is seeking solutions to treat these diseases using various platform technologies and drug development strategies. It also conducts studies in areas such as reducing and preventing the side effects of cancer treatments on the skin.
As it is known, the skin is the largest organ of the body that completely covers the outer surface of the body. In parallel, dermatological diseases come to the fore as common health problems affecting millions of people around the world. The products developed by Alys Pharmaceuticals play a potentially important role in meeting the needs of these patients.
Source link: https://webrazzi.com/2024/02/12/saglik-girisimi-alys-pharmaceuticals-100-milyon-dolar-yatirim-aldi/